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Summary
AMP-activated protein kinase (AMPK) is a key sensor and regulator of intracellular and whole-body energy metabolism. We
have identified a thienopyridone family of AMPK activators. A-769662 directly stimulated partially purified rat liver AMPK
(EC50 = 0.8 mM) and inhibited fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 mM). Short-term treatment of normal
Sprague Dawley rats with A-769662 decreased liver malonyl CoA levels and the respiratory exchange ratio, VCO2/VO2, indi-
cating an increased rate of whole-body fatty acid oxidation. Treatment of ob/ob mice with 30 mg/kg b.i.d. A-769662
decreased hepatic expression of PEPCK, G6Pase, and FAS, lowered plasma glucose by 40%, reduced body weight gain
and significantly decreased both plasma and liver triglyceride levels. These results demonstrate that small molecule-
mediated activation of AMPK in vivo is feasible and represents a promising approach for the treatment of type 2 diabetes
and the metabolic syndrome.Introduction
Obesity and associated diseases like type 2 diabetes, the meta-
bolic syndrome, hypertension, and atherogenic dyslipidemia are
major and growing health risks. Each of these conditions is
frequently associated with reduced insulin action and impaired
glucose and lipid metabolism, resulting in significantly increased
cardiovascular risk. AMPK, a heterotrimeric serine/threonine
kinase widely recognized as a key regulator of fatty acid and
glucose homeostasis (Hardie et al., 2003; Kahn et al., 2005), is
emerging as an attractive target for the treatment of these
conditions.
AMPK is involved in the regulation of whole-body energy me-
tabolism, as evidenced by the fact that two adipose tissue-
derived hormones, leptin and adiponectin, modulate AMPK
activity (Minokoshi and Kahn, 2003; Minokoshi et al., 2002;
Steinberg et al., 2003; Tomas et al., 2002; Wu et al., 2003;
Yamauchi et al., 2002). AMPK appears to mediate the action of
leptin in skeletal muscle where leptin-induced AMPK activation
increases fatty acid oxidation. Adiponectin, previously identified
as a regulator of glucose and lipid metabolism (Goldstein and
Scalia, 2004), also stimulates AMPK activity in skeletal muscle
and liver resulting in increased fat oxidation in muscle and liver,
increased glucose transport in muscle, and decreased hepatic
glucose production. The role of AMPK in regulating whole-
body energy metabolism is further emphasized by studies ofCELL METABOLISM 3, 403–416, JUNE 2006 ª2006 ELSEVIER INC. DOAMPK catalytic a2 subunit specific knockout (KO) or overex-
pressing mice. The a2-specific knockout mice exhibit glucose
intolerance and insulin resistance, reduced muscle glycogen
synthesis, and chronically elevated free fatty acid levels (Viollet
et al., 2003). In a more recent study, on a high-fat diet, a2 KO
animals exhibited increasedbodyweight coupledwith increased
fat mass due to enlarged adipocyte cell size (Villena et al., 2004).
In contrast, acute hepatic overexpression of a constitutively ac-
tive a2 subunit results in reduced blood glucose and increased
hepatic fatty acid oxidation, suggesting a preference for fatty
acid utilization in supplying energy needs (Foretz et al., 2005).
On a cellular level, AMPK plays a role as an energy sensor and
regulator. Under conditions of energy depletion, AMPK inhibits
ATP-consuming pathways (e.g., fatty acid synthesis, cholesterol
synthesis, and gluconeogenesis) and stimulates ATP-generat-
ing processes (e.g., fatty acid oxidation and glycolysis), thus
restoring overall cellular energy homeostasis (Carling, 2004;
Hardie, 2003). In regulating glucose metabolism, AMPK activa-
tion suppresses expression of two key gluconeogenic enzymes,
PEPCK and glucose-6-phosphatase which in turn inhibits
gluconeogenesis. This suppression of gluconeogenic gene ex-
pression has been demonstrated with the nonspecific AMPK
activator, 5-aminoimidazole-4-carboxamide riboside (AICAR),
in hepatoma cells (Lochhead et al., 2000) and also in vivo follow-
ing adiponectin administration (Yamauchi et al., 2002) or adeno-
virus-mediated delivery of a constitutively active AMPK (ForetzI 10.1016/j.cmet.2006.05.005 403
A R T I C L EFigure 1. Thienopyridone structure, enzymatic potency, reversibility, and selectivity
A) The general structure of the thienopyridones and the structures of A-592107, the original screening hit, and A-769662, an optimized thienopyridone.
B) Stimulation of partially purified rat liver AMPK. Activity was monitored by measuring 33P-phosphorylation of the SAMS peptide substrate.
C) Activation of the baculovirus/Sf9 expressed isoform of AMPK, a1b1g1.
D) GPPase activity was measured in the presence of glycogen using a phosphoglucomutase and glucose-6 phosphate dehydrogenase-coupled spectrophotometric
method. Effects of test compounds are expressed as a percent of the maximum stimulation achieved by AMP.404 CELL METABOLISM : JUNE 2006
Small molecule AMPK activatoret al., 2005; Viana et al., 2006). In addition, AMPK activation
acutely increases glucose uptake (via Glut1 and Glut4) and
chronically increases Glut 4 expression (Hardie and Hawley,
2001). In lipid metabolism, AMPK activation results in the phos-
phorylation and inactivation of acetyl-CoA carboxylase (ACC)
(Carling et al., 1987), a direct AMPK substrate, leading to de-
creased conversion of acetyl-CoA to malonyl CoA. AMPK activa-
tion also results in phosphorylation and activation ofmalonyl-CoA
decarboxylase (MCD) (Saha et al., 2000), resulting in further
lowering of malonyl CoA levels. Malonyl CoA allosterically
inhibits carnitine palmitoyl-CoA transferase (CPT1), the enzyme
responsible for transport of long chain acyl-CoAs intomitochon-
dria for oxidation (McGarry and Brown, 1997). Therefore,
a reduction in malonyl CoA levels leads to deinhibition of
CPT1 and hence increases fatty acid oxidation. Additionally,
as malonyl CoA is required for de novo synthesis of fatty acids,
decreasedmalonyl CoA leads to a reduction in hepatic fatty acid
synthesis (Ruderman and Prentki, 2004).
The enzymatic activity of AMPK is stimulated through phos-
phorylation of threonine-172 on the catalytic a subunits by an
upstream AMPK kinase and through allosteric activation by
AMP (Hardie et al., 2003; Hawley et al., 2003; Kemp et al.,
1999) through CBS (cystathionine b-synthase) domains on the
g subunits (Scott et al., 2004). Aside fromAMPand related nucle-
otides such as ZMP, presumed to bind at the AMP binding sites,
to date, direct AMPK activators have not been described.
Although the antidiabetic agents metformin and thiazolidine-
diones (TZDs) can stimulate AMPK activity in certain cellular
environments (Fryer et al., 2002; Musi et al., 2002; Saha et al.,
2004; Zang et al., 2004; Zhou et al., 2001; Zou et al., 2004), these
effects appear to be indirect. AICAR, due to its intracellular
conversion to ZMP, has been widely used to stimulate AMPK.
However, ZMP also acts as a potent AMP analog to stimulate
glycogen phosphorylase (GPPase) (Longnus et al., 2003; Young
et al., 1996) and inhibit fructose-1,6-bisphosphatase (FBPase)
(Vincent et al., 1991). Therefore, it is unclear whether the various
metabolic effects seen with AICAR administration are mediated
primarily through AMPK stimulation.
Through its central role in the regulation of glucose and lipid
metabolism, AMPK is a promising molecular target for the
treatment of diabetes and the metabolic syndrome (Winder
and Hardie, 1999). In order to further elucidate the physiological
consequences of AMPK activation we have identified and
characterized a family of small molecules that directly activate
AMPK in vitro and in vivo.
Results and discussion
Structure and enzymatic activity of small molecule
AMPK activators
By monitoring phosphorylation of the SAMS peptide, a widely
used substrate for AMPK (Davies et al., 1989), we screened
a chemical library of over 700,000 compounds (Anderson
et al., 2004), using partially purified rat liver AMPK and identified
a nonnucleoside thienopyridone as a direct activator of AMPKCELL METABOLISM : JUNE 2006(Figure 1A). The thienopyridone family is defined as shown in
Figure 1A. A-592107 stimulated partially purified rat liver
AMPKwith a potency comparable to AMP (EC50 = 38 mMversus
56 mM, respectively, Figure 1B) andwith similar maximal activity.
Subsequent optimization of this original screening hit led to the
synthesis of structurally related AMPK-activators, culminating in
the identification of A-769662 (EC50 = 0.8 mM, Figures 1A and
1B). A-769662 was equally potent in activating the baculovirus
expressed a1,b1,g1 recombinant isoform of AMPK (EC50 =
0.7 mM, Figure 1C). To determine if A-769662 is a reversible ac-
tivator, liver AMPK was preincubated with a 20-fold excess of
A-769662, followed by dilution to achieve the 13 drug concen-
tration routinely used in the standard assay format. Activation
observed with or without preincubation was equivalent, indicat-
ing that A-769662-induced AMPK activation occurs by revers-
ible binding (data not shown). Both A-592107 and A-769662
activate AMPK purified from multiple tissues and species in
a dose-responsive manner with modest variations in observed
EC50s (Table S1 in the Supplemental Data available with this
article online). EC50s determined for A-769662 using partially
purified AMPK extracts from rat heart, rat muscle, or human
embryonic kidney cells (HEKs) were 2.2 mM, 1.9 mM, or 1.1 mM,
respectively.
The enzymes GPPase and FBPase are allosterically modu-
lated by AMP and ZMP (Longnus et al., 2003; Vincent et al.,
1991; Young et al., 1996). AMP activates GPPase, whereas it
inhibits FBPase. To assess the specificity of A-592107 and
A-769662 for AMPK-activation, we determined their effects on
these two enzymes in vitro. A-592107 and A-769662 had no
effect on GPPase activity at concentrations up to 1 mM, while
the EC50 of AMP for the activation of GPPase was 19.2 mM
(Figure 1D). Similarly, neither compound showed significant in-
hibitory effect on FBPase at concentrations up to 100 mM, while
AMP significantly inhibited FBPase (IC50 = 1.0 mM, Figure 1E).
These results indicate that unlike AICAR/ZMP, A-592107 and
A-769662 are not general AMPmimetics but selectively activate
AMPK. To further establish the specificity of A-769662, we eval-
uated binding activity of A-769662 against a panel of 67 recep-
tors and ion channels (Cerep, Paris, France) and found no signif-
icant cross-reactivity at a concentration of 10 mM.
The observation that A-769662 does not affect GPPase and
FBPase activities (whereas AMP potently regulates these
enzymes) strongly suggests that A-769662 stimulates AMPK
activity in a manner that differs from AMP. To further address
this issue, we evaluated the additivity of AMP and A-769662me-
diated AMPK stimulation. A-769662 increased AMPK activity in
the presence of a saturating concentration of AMP (Figure 1F)
and AMP stimulated AMPK in the presence of a maximally
efficacious concentration of A-769662 (Figure 1G). This further
supports the hypothesis that A-769662 binds at a unique site
that differs from that of AMP binding.
Thienopyridone efficacy in primary rat hepatocytes
Activation of AMPK increases phosphorylation of various down-
stream target proteins including ACC (Carling et al., 1987), a keyE) FBPase activity was determined using the substrate D-fructose-1,6-bisphosphate and colorimetric detection of free phosphate. Results are expressed as percent
inhibition relative to vehicle control.
F) A-769662 dose-responsive AMPK activation and additive activation in the presence of 300 mM AMP.
G) AMP dose-responsive AMPK activation and additive activation in the presence of 10 mM A-769662.
Assay results presented in panels (B) through (G) are means6 SD from experiments run in triplicate and are representative of a minimum of two independent experiments.405
A R T I C L EFigure 2. Thienopyridones increase ACC phosphorylation and decrease fatty acid synthesis in the absence of cytotoxicity in primary rat hepatocytes
A) Western blot analysis of total ACC or the phosphorylated form of ACC in cell lysates from primary rat hepatocytes treated for 4 hr with AICAR or A-769662.
B) Fatty acid synthesis was measured as incorporation of 14C-acetate into fatty acids in primary rat hepatocytes during a 4 hr treatment with increasing concentrations of
AICAR, A-592107, or A-769662. Results are given as percent inhibition of fatty acid synthesis relative to the vehicle control and are means 6 SD from experiments run in
triplicate and are representative of a minimum of four independent experiments.
C) Spotfire analysis showing correlation between thienopyridone potencies for AMPK activation and for inhibition of fatty acid synthesis.
D)Results of cytotoxity assays run in primary rat hepatocytes usingMTS reagents and comparing a known cytotoxin, staurosporine, and A-769662. Data is from aminimum
of 10 experiments run in triplicate and is given as means 6 SD.enzyme in the regulation of fatty acid metabolism. The phos-
phorylation and hence inactivation of ACC results in decreased
levels of malonyl CoA which in turn activates CPT1 to increase
fatty acid oxidation and reduce de novo fatty acid synthesis
(Ruderman et al., 2003). A 4 hr treatment of primary rat hepato-
cytes with A-769662 or AICAR dose-dependently increased
ACC phosphorylation, as detected by Western blot analysis
using a phospho-specific antibody targeted to serine-79 (Fig-
ure 2A), a site specifically phosphorylated by AMPK (Davies
et al., 1990). There was no commensurate change in overall
ACC protein levels following drug treatment (Figure 2A). The
increased ACC phosphorylation correlated with inhibition of406fatty acid synthesis as measured by incorporation of 14C-ace-
tate into fatty acids, with IC50s of 53 and 3.2 mM for A-592107
and A-769662, respectively (Figure 2B). A-769662 also inhibited
fatty acid synthesis in mouse hepatocytes (IC50 = 3.6 mM, data
not shown). These results indicate that both compounds show
cellular potencies comparable to those seen in the enzymatic
assays using partially purified AMPK. In order to provide
a more global comparison of results from the two assays, we
performed a Spotfire correlation analysis of data from approxi-
mately 170 compounds. As shown in Figure 2C, the EC50s and
IC50s generated from enzymatic and cellular assays of the struc-
turally related thienopyridones demonstrated a good correlationCELL METABOLISM : JUNE 2006
Small molecule AMPK activatorbetween the enzymatic potencies and the inhibition of fatty acid
synthesis (R = 0.596).
To eliminate the possibility that the inhibition of fatty acid syn-
thesis could be mediated in part by cytotoxicity, we assessed
the potential cellular cytotoxicity of the compound series using
a colorimetricMTS assay. This assaymeasures the bioreduction
of a tetrazolium salt into a formazan product by dehydrogenase
enzymes in metabolically active cells. Treatment of rat hepato-
cytes with A-769662 at concentrations up to 100 mM showed
no measurable cytotoxicity, whereas effects of a known
cytotoxic agent, staurosporine, were significant (Figure 2D).
Although we demonstrated that A-769662 directly activates
AMPK in vitro we wanted to further probe the mechanism of ac-
tion by assessing whether this compound alters the cellular
levels of AMP, ADP or ATP. As shown in Table 1, A-769662 treat-
ment at concentrations up to 100 mM caused no significant
alterations in ATP and AMP levels in primary rat hepatocytes.
Taken together, these results indicate the thienopyridone
AMPK activators exert their cellular effects by direct activation
of AMPK activity and not as a consequence of cellular stress,
toxicity, or by altering the AMP/ATP ratio.
Acute treatment of SD rats with A-769662
Since AMPK activation inhibits ACC activity, one expected in
vivo consequence is a decrease in malonyl CoA levels, leading
to reduced lipogenesis and increased fatty acid oxidation. To
evaluate this hypothesis we studied the effects of A-769662
on whole-body fatty acid oxidation by indirect calorimetry.
Sprague Dawley (SD) rats that were fed ad libitum prior to the
study were first acclimated by placing them in a gas exchange
indirect calorimeter without food for 2 hr. The animals were
then gavaged with a mixed meal [Glucerna (12 ml/kg) plus raw
cornstarch (0.5 g/ml)], along with administration of either 30
mg/kg A-769662 (i.p.), 500 mg/kg metformin (oral) or vehicle
(i.p.), and monitored for oxygen consumption and CO2 produc-
tion for the remaining 14 hr. Vehicle-treated rats preferentially
oxidized carbohydrates after themeal bolus as indicated by a re-
spiratory exchange ratio (RER) of close to 1, which is indicative
of approximately 100% carbohydrate utilization. In contrast,
a single dose of A-769662 or metformin significantly reduced
the RER relative to vehicle (RER = 0.81 or 0.86, respectively)
throughout the first 3 hr after treatment, indicating increased
fatty acid utilization despite the availability of carbohydrates
(Figure 3A). This reduction in RER by A-769662 was followed
by a small but significant increase in RER versus vehicle over
the subsequent 3 hr. The relatively short plasma t1/2 of this com-
pound (approximately 3 hr) may explain the transient nature of
the single dose effect.
Table 1. Nucleotide levels following 4 hr treatment of primary rat hepatocytes
with A-769662
A-769662
Concentration
AMP
(nmol/106 cells)
ADP
(nmol/106 cells)
ATP
(nmol/106 cells) AMP:ATP
Untreated 0.35 0.78 6.21 0.057
1 mM 0.25 0.89 6.63 0.037
10 mM 0.4 0.93 6.34 0.063
100 mM 0.35 0.95 7.48 0.047
Values given are individual determinations that are representative of three inde-
pendent experiments.CELL METABOLISM : JUNE 2006In conjunction with increased ACC phosphorylation in primary
rat hepatocytes, we anticipated reduced malonyl CoA levels fol-
lowing drug treatment. SD rats were treated with A-769662 or
metformin following the same feeding and dosing regimen as
described for the indirect calorimetry study above. Liver and
muscle tissues were harvested at 1.5 hr postmeal and drug
treatment and malonyl CoA levels were measured by LC/MS.
We observed 33% and 58% reductions of malonyl CoA levels
in livers of animals treated with 30 mg/kg A-769662 (0.905
nmol/g) or 500 mg/kg metformin (0.574 nmol/g), respectively,
relative to vehicle controls (1.36 nmol/g, Figure 3B). In addition,
we observed a statistically nonsignificant decrease (24%6 7%,
Figure 3. Reduced RER and malonyl CoA levels in SD rats following single treat-
ment with A-769662
Whole-body substrate oxidation, as indicated by the respiratory exchange ratio
(RER), and malonyl CoA levels in Sprague Dawley rats treated with a single dose
of either vehicle, A-769662 or metformin.
A) SD rats were given a single dose of either vehicle (i.p., n = 12), metformin
(p.o., n = 8), or A-769662 (i.p., n = 12) at 4:30 PM (at the initiation of the dark cycle,
see Experimental Procedures section) and RER was monitored in an Oxymax
chamber for 14 hr. RER values of 0.7 and 1.0 indicate 100% fatty acid and
100% carbohydrate oxidation, respectively. All values are means6 SEM. *, **, ***,
p < 0.05, < 0.01, < 0.001,versus vehicle, respectively.
B) Malonyl CoA levels were measured in liver and skeletal muscle of SD rats
treated as described above. Values are means 6 SEM (nR 6).407
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p = 0.068) inmalonyl CoA levels in skeletal muscle of rats treated
with A-769662.
Chronic treatment of ob/ob mice with A-769662
The acute reduction of malonyl CoA levels in SD rats by
A-769662 prompted us to further examine the compound in
a chronic model. A-769662 was evaluated in diabetic ob/ob
mice during 5 (Figure 4) or 14 day (Figure 5) dosing. Since oral
bioavailability was poor (F = 7%), animals were dosed twice
daily by i.p. injection. Metformin (5 and 14 day studies) and
AICAR (5 day study) were included as controls. In both studies
a 30 mg/kg, b.i.d. dose of A-769662 significantly decreased
fed plasma glucose (30%–40% reduction, relative to vehicle),
while the lower doses (3 and 10 mg/kg) of A-769662 had no
effect (Figures 4A and 5A). On the final day of the studies, the
1 hr postdose glucose level observed with A-769662 (30 mg/kg)
was similar to that seen with AICAR (375 mg/kg) or metformin
(450 mg/kg). However, the glucose lowering effects of
A-769662 (30 mg/kg) in both studies were more sustained than
those observed with AICAR or metformin. In the 5 day study,
fed glucose levels (16 hr postdose) were lowered by 42%, 7%,
or w2% (compared to vehicle control), following A-769662,
AICAR, or metformin treatment, respectively (data not shown).
Postprandial insulin levels were not different from vehicle with
any of the treatments in the 5 or 14 day studies (data not shown).
In addition to glucose lowering, overall lipid metabolism was
modified by A-769662. Plasma samples harvested 1 hr post
last dose showed a significant reduction of plasma triglyceride
(TG) levels following treatment with A-769662 (30 mg/kg) or
AICAR (375 mg/kg) by 54% or 63%, respectively (Figure 4B).
There was also a modest reduction in body weight gain in ob/ob
mice treated with 30 mg/kg A-769662 for 5 days (Figure 4C).
In the subsequent 14 day study, this initial effect was followed
by normal weight gain, similar to that seen in the vehicle control
group (Figure 5B). However, at sacrifice in the 14 day study,
body weights for the 30 mg/kg A-769662 ob/ob group remained
9% lower compared to the vehicle control group. Interestingly,
this reduction in body weight was accompanied by reductions
in liver and epididymal fat padweights of 27%and 17%, respec-
tively (data not shown), suggesting that lowered fat content
most likely accounts for the decreased body weight. Liver TG
content decreased dramatically after 5 days of treatment with
both doses of A-769662, AICAR, or metformin as assessed by
Oil Red O lipid staining (Figure 4D). In addition, by direct mea-
surement of liver triglyceride levels, we observed a statistically
significant and dose-responsive lowering by 26% or 48%
(relative to vehicle controls) in animals treated with 3 mg/kg or
30 mg/kg A-769662, respectively (Figure 4E). Liver TGs wereCELL METABOLISM : JUNE 2006also lowered significantly (39% and 30%, respectively) in AICAR
andmetformin treated animals. A decrease in liver TGs was pre-
viously observed subsequent to AICAR treatment in fed ob/ob
mice (Song et al., 2002), in high-fat fed rats (Iglesias et al.,
2002) and in ZDF rats. However, in contrast with our results
and with the results mentioned above, it should be noted that
AICAR treatment has been shown to increase liver weight by
unknown mechanisms in nonobese rats (Winder et al., 2000)
and in obese Zucker (fa/fa) rats, with an accompanying loss of
intraabdominal fat (Buhl et al., 2002). In a more recent short-
term study, delivery of adenovirus encoding constitutively active
AMPKa2 targeted specifically to liver increased hepatic lipid
Figure 5. ob/ob 14 day study showing reduced plasma glucose
Treatment groups were: ob/ob vehicle or A-769662 (3, 10, or 30 mg/kg, i.p., b.i.d.)
or lean littermates treated with vehicle or A-769662 (30 mg/kg) (n = 10 per group).
A) Postprandial plasma glucose levels measured 1 hr post final dose.
B) Body weights at study initiation and over the course of the study.
All values are means 6 SEM. p values as described in Figure 3.
Small molecule AMPK activatorFigure 4. Reduced plasma glucose levels, lipids, and ACC activity in 5 day ob/ob study
6- to 7-week-old ob/ob and lean littermate mice were studied at baseline and after 5 days treatment (at 8 AM, see Experimental Procedures section). Treatment groups
were as follows: ob/obmice treated with vehicle (0.2% hydroxypropyl methylcellulose [HPMC], i.p., b.i.d.), A-769662 (3 or 30 mg/kg, i.p., b.i.d.), AICAR (375 mg/kg, s.c.,
b.i.d.), or metformin (450 mg/kg, p.o., q.d.), and lean littermates treated with vehicle (i.p., b.i.d.), (n = 10 per group).
A) Postprandial plasma glucose levels were measured 1 hr post final dose on day 5.
B) Plasma triglyceride levels on day 5 (1 hr post final dose).
C) Body weights were taken at study initiation and on day 5.
D) Liver fat area fraction was determined by Oil Red O staining at sacrifice (4–5 livers per group were sectioned, stained, and analyzed using MetaMorph image analysis
software).
E) In another identical 5 day ob/ob study, triglyceride levels were determined in livers from fed animals using the Infinity Triglyceride Reagent (nR 4).
F) ACC activity in liver was measured after sacrifice and tissue harvest (n = 6).
G) Distribution of A-592107 and A-769662 in tissues harvested 1 hr after final dose (n = 10, except for brain n = 5) is represented as the compound level in tissue divided by
its IC50 in the fatty acid synthesis cellular assay.
All values are means 6 SEM. p values as described in Figure 3.409
A R T I C L Edeposition, as measured by Oil Red O staining (Foretz et al.,
2005). Clearly, in our studywe did not observe increased hepatic
lipid accumulation with A-769662 or AICAR treatment. These re-
sults point to a need for further study to clarify the overall conse-
quences of altering lipid and glucose metabolism via AMPK ac-
tivation, and to the likelihood of animal model and dosing
paradigm-dependent variations in findings. We also monitored
food consumption in the 14 day study and observed a modest,
transient reduction in food intake with A-769662 at 30 mg/kg
(5.5 versus 4.5 g/24 hr/mouse) compared to vehicle control.
However, no changes in food consumption or body weight
(Figure 5B) were observed in lean control mice treated with
A-769662 at 30 mg/kg. Additionally, core body temperatures,
ALT and AST levels remained unchanged with any of the treat-
ments (data not shown).
To prove that the altered liver fat content observed following
A-769662 treatment is mechanism based through AMPK activa-
tion, we measured ACC activity in tissues derived from a 5 day
ob/ob study (Figure 4F). Liver from animals treated with 30 mg/kg
A-769662 showed a reduction in ACC activity (179 cpm/mg/
min) relative to vehicle control (244 cpm/mg/min). A significant
reduction in ACC activity was also noted with 375 mg/kg AICAR
(179 cpm/mg/min) and 500 mg/kg metformin (213 mg/kg/min).
While we focused on the role of ACC in altering liver fat con-
tent, AMPK has also been strongly implicated in the regulation
of sn-glycerol-3-phosphate acyltransferase (G3PAT) activity
(Muoio et al., 1999). Since G3PAT catalyzes the committed
step in glycerolipid biosynthesis thus playing a regulatory role
in the partitioning of acyl-CoA toward b-oxidation, the potential
exists for A-769662 to be exerting it’s influence on lipid metab-
olism through multiple mechanisms in addition to modulation
of ACC activity.
HPLC analysis of tissue drug exposures revealed that
A-769662 reached the highest concentration in liver, with much
lower levels in muscle, and almost undetectable levels in brain
(Figure 4G). We used compound concentrations required for
the inhibition of fatty acid synthesis in isolated hepatocytes as
a comparator for compound levels observed to elicit pharmaco-
dynamiceffects.Compoundconcentrationsobserved in liver 1 hr
after administration of 30 mg/kg or 3 mg/kg of A-769662 were
approximately 30-fold or 2.5-fold, respectively, above thecellular
IC50 for fatty acid synthesis. In muscle, the cellular IC50 was
exceeded by 2.2-fold after 30 mg/kg A-769662, but was not
reached at 3mg/kg. It is tempting to speculate that a higher expo-
sure in skeletalmusclewould lead to amore sustained increase in
overall whole-body fatty acid oxidation and energy expenditure.
Since glucose lowering following A-769662 treatment was
observed in both the 5 and 14 day study, we evaluated the
potential mechanism leading to this result by quantitating gluco-
neogenic gene expression. Previous studies showed a decrease
in PEPCK and/or glucose-6-phosphatase (G6Pase) expression
in vitro subsequent to AICAR or metformin treatment (Lochhead
et al., 2000; Morioka et al., 2005) In vivo, suppression of gluco-
neogenic gene expression in conjunction with AMPK activation
was reported in mouse liver following injection of full-length
adiponectin (Yamauchi et al., 2002) or during short-term overex-
pression of constitutively active AMPK via adenovirus-mediated
gene transfer (Foretz et al., 2005; Viana et al., 2006). To explore
the possible mechanism responsible for glucose lowering with
A-769662, we evaluated PEPCK, G6Pase, and FAS (fatty acid
synthase) gene expression in liver following an acute (24 hr) or410chronic (5 day) treatment using real-time quantitative RT PCR
analysis (Figure 6A). For both treatment durations, animals
were fasted overnight prior to sacrifice, and the livers were
harvested 1 hr post final dose.
In the acute treatment (Figure 6A), A-769662 had no significant
effects on PEPCK, G6Pase or FAS. In contrast, PEPCK gene
expression was modestly but significantly decreased with
AICAR (19%). To our surprise, however, there was a dramatic
increase in G6PasemRNA expression (435%), as well as amod-
est induction of FAS mRNA (62%) by AICAR. Metformin did not
significantly regulate PEPCK or G6Pase but FAS gene expres-
sion was lowered by 35%. We extended these findings by eval-
uating hepatic gene expression following 5 days of treatment
(Figure 6A), where we observed a significant decrease in PEPCK
(37%), G6Pase (63%), and FAS (31%) mRNA expression with
A-769662. In contrast, AICAR decreased PEPCK expression
(30%) and, similar to the acute study, increased G6Pase
(325%) and FAS (100%) mRNA expression. We did not detect
significant changes in gene expression following 5 day metfor-
min treatment. Based on these findings we believe that
A-769662 most likely mediates its metabolic actions in part via
hepatic AMPK activation leading to modulation of gluconeo-
genic gene expression.
Because the effect of AICAR on G6Pase and FAS expression
was entirely unexpected, we evaluated PEPCK, G6Pase, and
FAS expression in liver samples from fed or fasted ob/ob and
lean mice under the identical PCR conditions used above. As
anticipated, we observed decreased PEPCK and G6Pase and
increased FAS expression in fed compared to fasted animals
(Figure 6B), thus validating the QPCR methodology used for the
geneexpressionanalysis.AlthoughAICARhasbeenshown tode-
crease PEPCK and G6Pase expression in vitro, (Lochhead et al.,
2000) comparable in vivo experiments have not been reported.
We speculate that AMPK-independent inhibition of FBPase by
AICAR (via ZMP) with resulting inhibition of gluconeogenesis in-
duces compensatory changes, including increased G6Pase, to
maintain hepatic glucose output. We currently have no explana-
tion for the unexpected increase in FAS mRNA observed after
AICAR treatment, but assume that it is not AMPK-mediated since
it was not observed with metformin or A-769662 treatment.
In contrast to AICAR, prolonged treatment with A-769662 not
only lowers PEPCK mRNA levels but, as anticipated, it also de-
creases G6Pase and FAS expression. These results are in good
agreement with previously published results demonstrating de-
creased PEPCK and G6Pase expression in ob/ob and strepto-
zotocin-induced diabetic mice following adenovirus-mediated
transfer of constitutively active AMPK (Foretz et al., 2005). Sim-
ilarly, the reduction in FAS expression subsequent to A-769662
treatment recapitulates results obtained in experiments in nor-
mal, fasted/refed mice following adenovirus-mediated overex-
pression of AMPK (Foretz et al., 2005) and in SD rats subsequent
to metformin treatment (Zhou et al., 2001).
Under fasting conditions, we demonstrated a decrease in glu-
coneogenic gene expression with A-769662 but did not observe
a significant decrease in glucose levels (data not shown). We
speculate that this discrepancy may be due to the timing of
gene regulation, the duration of fasting period, or the much
smaller difference in glucose levels observed between the
ob/ob vehicle and the lean control mice with overnight fasting.
However, the robust glucose lowering observed under fed con-
ditions accompanied by the decrease in PEPCK and G6PaseCELL METABOLISM : JUNE 2006
Small molecule AMPK activatorFigure 6. Reduced gluconeogenic gene expression and lack of Akt phosphorylation with A-769662
6- to 7-week-old ob/ob and lean littermate mice were studied after 24 hr or 5 days treatment (at 8 AM, see Experimental Procedures section and Figure 4 legend). Animals
were dosed as previously described but fasted overnight and the tissues harvested 1 hr post last dose.
A)Real-time quantitative RT PCR analysis was used to measure PEPCK, G6Pase, and FASmRNA levels in RNA samples from livers of fasted animals. PCRwas performed
in duplex including primers to 28S RNA for normalization. The 5 day results shown are representative of two independent animal experiments (nR 9).
B)Real-time quantitativemRNA analysis was done using liver RNA samples from fed (a subset of mice, n = 5 per group, were fed overnight prior to dosing and sacrifice) and
fasted animals and PEPCK, G6Pase, and FAS mRNAs measured. As above, all samples were run in duplex with 28S RNA (nR 4).
All values given are means 6 SEM. p values as given in Figure 3.
C) Total Akt or phospho-Akt levels in protein lysates from livers of fed animals as detected by Western analysis.expression in A-769662 treated animals strongly suggests that
the decreased expression of gluconeogenic genes contributes
to the modulation of glucose levels by A-769662.CELL METABOLISM : JUNE 2006As in our previous 14 day study, estimated food intake was
monitored in a 5 day study. In agreement with the 14 day study,
we observed a transient decrease in estimated food intake in the411
A R T I C L E30 mg/kg A-769662 dose group (w42% at day 3, p < 0.05 ver-
sus vehicle) but this level was similar to that observed for AICAR
and metformin. As mentioned in the Experimental Procedures
section, the ob/ob mice were group-housed, 5 animals/cage,
therefore we can only provide a crude estimate of individual
food intake. In the 14 day study, glucose lowering was accom-
panied by food intake and body weight normalization to near
vehicle control levels, suggesting that decreased food intake
most likely is not the primary mechanism for glucose and lipid
lowering. Furthermore, in the 5 day study, food intake was mea-
sured on day 3, while treatment efficacy was determined on day
5 when food intake was increasing. However, we cannot com-
pletely rule out the possibility that the transient reduction in
food intake influenced the observed endpoint efficacy including
changes in gene expression.
Weight loss might be expected with prolonged peripheral
tissue stimulation of the AMPK pathway and the resultant inac-
tivation of ACC. Increased lipid oxidation and energy expendi-
ture combined with resistance to high fat diet-induced weight
gain was observed in ACC2 knockout mice (Abu-Elheiga et al.,
2003). In addition, AMPK KO mice subjected to a high-fat
diet exhibit increased body weight and fat mass, relative to
wild-type controls (Villena et al., 2004). The results described
above illustrate the significance of AMPK activation and ACC2
regulation in sustaining energy homeostasis and in regulating
whole-body metabolism. Conversely, recent reports describe
increased food intake in animals i.c.v. injected with AICAR
(Andersson et al., 2004; Kim et al., 2004), indicating a divergence
in the effects of peripheral versus central AMPK activation.
The lack of increased food intake in A-769662-treated animals
could be due to the absence of compound exposure in the
brain.
We also questioned whether the effects of A-769662 could be
due to action through an alternate, AMPK-independent, sec-
ondary pathway. We examined Akt phosphorylation and found
no changes in phosphorylated (active) Akt levels in livers from
5 day A-769662-treated animals (Figure 6C), arguing against
secondary effects of A-769662 via the Akt pathway.
Taken together, our results indicate that specific, small mole-
cule-mediated activation of AMPK improves overall glucose and
lipid metabolism. Based on the tissue distribution of our com-
pounds, it is likely that the effects observed in mice are primarily
due to stimulation of AMPK in liver. The decrease in plasma and
liver TG levels can be explained by increased oxidation and de-
creased synthesis of fatty acids in liver. This decrease in hepatic
lipid accumulation will subsequently improve insulin-sensitivity,
resulting in improved glucose metabolism. Although compound
exposure in skeletal muscle of mice treated with 30 mg/kg A-
769662 was modest, we cannot exclude the possibility that
AMPK activation in skeletal muscle contributes to the whole-
body efficacy observed with A-769662. However, there is litera-
ture precedence demonstrating the impact of liver targeted
AMPK activation. A recent study of short-term, liver specific,
overexpression of a constitutively active form of AMPKa2 in
obese and diabetic mouse models highlights many of the
expected benefits of AMPK activation (Foretz et al., 2005). Liver
selective AMPK overexpression led to decreased blood glucose
levels and gluconeogenic gene expression in normal, streptozo-
tocin-induced and ob/ob diabetic mice and to decreased
circulating lipid levels and increased hepatic fatty acid oxidation
in normal C57BL/6j mice (Foretz et al., 2005). Thus, the liver412specific AMPK activation was sufficient to induce a switch
from glucose to fatty acid utilization to supply energy needs.
Many of the studies validating AMPK stimulation as a potential
target for the treatment of type 2 diabetes, obesity and the
metabolic syndrome have utilized AICAR as a tool to induce
AMPK activation. Since AICAR is metabolized to ZMP, an AMP
mimetic, it clearly has additional effects that are independent
of AMPK activation. In both rat hepatocytes (Vincent et al.,
1991) and inmice in vivo (Vincent et al., 1996) AICARwas shown
to dose-dependently inhibit fructose-1,6-bisphosphatase activity
hence potently inhibiting gluconeogenesis. More recently, met-
formin and TZDs have been shown to activate AMPK, however,
both of these agents are indirect and nonselective. While AMPK
activation is an attractive approach for the regulation of lipid and
glucose metabolism, studies utilizing direct and selective AMPK
activators as with the current study are needed to clearly isolate
and elucidate the myriad effects of AMPK activation.
Overall, our results demonstrate that small molecule-mediated
direct stimulation of AMPK in vivo is feasible. Our data also
strengthen the hypothesis that AMPK activation primarily di-
rected to liver can affect whole-body intermediary metabolism
with improvements in circulating levels of glucose and lipids.
This further supports the potential of AMPK as a drug target
for the treatment of diabetes and the metabolic syndrome.
Experimental procedures
Preparation of enzyme
Following a previously described modification (Anderson et al., 2004) of an
established protocol (Hawley et al., 1996), partially purified AMPK was pre-
pared from rat livers, hearts or skeletal muscles (Pel Freez, Rogers, Arizona).
To purify AMPK from HEK293 cells, frozen cell pellets were homogenized in
the previously described Buffer A containing EDTA-free protease inhibitor
(Roche Diagnostics GMBH) and Benzonase (EM Industries, Hawthorne,
New York). The homogenate was centrifuged 30 min at 10,000 3 g and the
supernate decanted, brought to 1% PEG (average 8000 MW) and mixed
for 30min. Following clarification of the sample by centrifugation the purifica-
tion proceeded as previously described and the active fractions were pooled
and concentrated using an Amicon stirred cell concentrator (Millipore).
The AMPK isoform, a1b1g1, was cloned and expressed in a baculovirus/
Sf9 system. Sf9 cells were grown in Sf900 II SFM media (Gibco, Carlsbad,
California) to a cell density of 2.5 3 106 cells/ml in Wave Bioreactors (Wave
Biotech, Bridgewater New Jersey), at which point the culture was infected
with three separate baculovirus stocks encoding the a, b, and g chains.
Each virus was added to a multiplicity of infection (MOI) of 2.0. Cells were
harvested 48 hr postinfection by centrifugation and the resulting paste
stored at 285ºC until processing following a modification of the protocols
described above.
All steps described above were carried out at 4ºC and all chemicals were
supplied by Sigma unless otherwise noted.
96-well AMPK assay
AMPK activity was measured by monitoring phosphorylation of the SAMS
peptide substrate (20 mM in standard assays and 100 mM in additivity assays)
following a previously described protocol (Anderson et al., 2004). To deter-
mine whether compound-induced AMPK activation occurs in a reversible
manner, AMP or A-769662 were preincubated with rat liver AMPK for 10
min at 20 times standard assay concentrations prior to dilution andmeasure-
ment of AMPK activity. Unless otherwise specified, chemicals used in the
above assay were supplied by Sigma.
Glycogen phosphorylase b assay
To assay glycogen phosphorylase b (GPb) activity (Kaiser et al., 2001), 1.5
mg/ml of rabbit GPbwas added to a reaction mix containing 20mMNa2HPO4
(pH 7.2), 2 mMMgSO4, 1 mM b-NADP (b-nicotinamide adenine dinucleotide
phosphate), 1.4 U/ml G-6-PDH (Glucose-6-Phosphate-Dehydrogenase) andCELL METABOLISM : JUNE 2006
Small molecule AMPK activator3 U/ml PGM (phosphoglucomutase). AMP or test compounds were added to
the assay medium at the specified concentrations followed by the addition of
glycogen (final concentration 1 mg/ml) to initiate the reaction. After incubat-
ing 10 min at 25ºC, GPb activity was assessed by measuring absorbance at
340 nm. All reagents for the GPb assay were from Sigma.
Fructose 1,6-bis-phosphatase assay
D-fructose-1,6 diphosphatase (FBPase, 0.01 U/ml final concentration) in 23
assay buffer, 100mM Tris (pH 7), 4 mMMgCl2, 300mMNaCl, 0.2 mg/ml BSA
and 6mMDTT, was added to test compounds to give final concentrations as
indicated. Substrate, D-fructose-1,6-diphosphate, at a final concentration of
0.1 mM was added to the reaction and the reaction mix was incubated at
30ºC for 20 min. Following the incubation 2 volumes of Malachite Green so-
lution (Upstate, Charlottesville, Virginia) containing 0.001% Tween 20 was
added and absorbance at 640 nm read immediately. Unless otherwise
stated, reagents used for this assay were supplied by Sigma.
ACC and Akt phosphorylation
For ACC studies, hepatocytes were isolated from 8 week old, male, Sprague
Dawley rats by collagenase (Sigma) digestion (Ulrich et al., 1995; Van den
Berghe et al., 1980). and plated at 1 3 106 cells per well in collagen coated
6-well plates (Becton Dickinson Labware). Following an overnight serum
starvation cells were treated for 4 hr with test compounds at the concentra-
tions described and lysed in RIPA buffer (PBS [Gibco], 1% NP40 [Sigma],
0.5% SDC, [Sigma], 0.1% SDS [Sigma], and Protease Inhibitor Cocktail
[Sigma]). For Akt studies, livers were homogenized using a Tissumizer (Tek-
mar Co., Cincinnati, Ohio) in a 1:10 volume (w/v) of RIPA buffer, homogenates
were centrifuged at 15,000 3 g for 60 min at 2ºC, and the upper lipid layer
removed by aspiration. Following electrophoresis and transblotting, total
ACC levels were measured using NeutrAvidin alkaline phosphatase (Pierce,
Rockford, Illinois) and the alkaline phosphatase substrate, Immunopure Fas-
tRed (Pierce). The primary, polyclonal antibodies used were specific for
phospho-ACC (Upstate, Lake Placid, New York), phospho-Akt (Cell Signal-
ing Technology, Beverly, Massachusetts) or Akt (Cell Signaling Technology).
In each case an HRP-conjugated secondary antibody (Amersham, Bucking-
hamshire, England) was used and Westerns were developed in ECL
(Amersham).
Fatty acid synthesis assay
The protocol described below is an adaptation of methods previously de-
scribed (Foretz et al., 1998; Garcia-Villafranca et al., 2003). Primary rat hepa-
tocytes were isolated as described above and plated at 53 104 cells per well
on BioCoat, collagen-coated, black-walled 96-well plates (Becton Dickinson
Labware, Bedford, Massachusetts) in DMEM (Gibco) supplemented with
10% FBS (Hyclone, Logan, Utah), 5 mM glucose (Sigma), 1 mM sodium
pyruvate (Gibco), 2 mM L-glutamine (Gibco), 25 mM HEPES (Gibco), 0.1 mM
nonessential amino acids (Gibco), 5 mg/ml transferrin (Gibco), 100 nM dexa-
methasone (Sigma), 100 nM insulin (Sigma) and 25 mg/ml gentamycin
(Gibco). After 4 hr medium was replaced with medium as described above
but without FBS and containing 100 nM triiodothyronine (T3) (Sigma). Follow-
ing a 16 hr, 37ºC incubation, the incubation medium was removed and re-
placed with medium containing 14C acetate (2 mCi/ml, Perkin Elmer) and AI-
CAR (Sigma) or test compounds at the indicated concentrations. Cells were
incubated 4 hr at 37ºC then the plates were rinsed with PBS (Gibco). The final
wash was replaced with Microscint20 (Perkin Elmer) and radioactivity incor-
porated into fatty acidmonitored on aWallac (Turku, Finland) Microbeta plate
reader.
Compound potencies in enzymatic and cellular assays were correlated by
Spotfire Decision Site analysis (Spotfire, Inc. Somerville, Massachusetts).
Cytotoxicity assay
Primary rat hepatocytes were isolated and treated as described for the fatty
acid synthesis assay. Following a 4 hr treatment with test compounds, me-
dium was removed from the cells and replaced with medium containing
MTS reagent (Promega, Madison,Wisconsin). Plates were incubated at
37ºC to allow for color development and cell viability was evaluated by con-
version of a tetrazolium salt into a formazon product measured spectropho-
tometrically at 490 nm.CELL METABOLISM : JUNE 2006AMP:ATP assay
Primary rat hepatocytes were plated and treated as described for the deter-
mination of ACC phosporylation. Following the 4 hr incubation with com-
pound, cells were washed with ice-cold PBS (Gibco) and the adenine nucle-
otides were extracted as previously described (Corton et al., 1994) with 500
ml/well HClO3. The acid was extracted with three treatments of 1.1 volumes of
1:1 tri-n-octylamine:1,1,2-trichlorotriflouroethane and 50-100 ml of the aque-
ous sample injected on a Whatman (Brockville, Ontario, Canada) Partisil 10
SAX column preequilibrated in Buffer A (10 mM K2PO4, [pH 6.75]). To elute,
sample columns were run for 5 min in Buffer A, then for 15 min in a linear gra-
dient to Buffer B (500 mM K2HPO4, [pH 5]) and finally for 35 min in Buffer B at
a flow rate of 2 ml/min. To measure nucleotide concentration absorbance
was read at 254 nm. Unless otherwise indicated, all reagents were supplied
by Sigma.
Animal care and treatment
ob/ob mice and their lean littermates (6–7 weeks of age, Jackson Laborato-
ries, Bar Harbor, Maine) and Sprague Dawley (SD) rats of 200-220 g (Charles
River, St. Louis, Missouri) were acclimated to the animal research facilities for
5 days. The following investigations were conducted in accordance with Ab-
bott Laboratories IACUC guidelines. ob/ob mice were housed 5 per cage,
and lean ob/+ littermates 2 per cage, and maintained on mouse chow (Lab-
diets #5015, St. Louis, Missouri) ad libitum. The SD rats were single housed
and were further acclimated to an indirect calorimeter gas exchange system
(Oxymax, Columbus Instruments, Columbus, Ohio), overnight on two occa-
sions prior to study.
Gas exchange in Sprague Dawley rats
After acclimation to the indirect calorimetery system the SD rats were taken
off their normal rat chow (Labdiets #5002, Richmond, Indiana) and given
a high-sucrose diet (Research Diets AIN-76A, 70% sucrose, New Brunswick,
New Jersey) as reported previously (Harwood et al., 2003). They were placed
in the indirect calorimeter at 2:30 PM, denied access to food, and 2 hr later
given an oral meal challenge, raw cornstarch (0.5 g/ml, ARGO, CPC Interna-
tional, Englewood Cliffs, New Jersey) in a mixed liquid meal of Glucerna (12
ml/kg, Abbott Laboratories, Columbus, Ohio), by gavage, immediately fol-
lowed by either vehicle (0.2% HPMC, i.p. n = 12), metformin (500 mg/kg,
p.o., n = 8), or A-769662 (30 mg/kg, i.p., n = 12). This mixed bolus of nutrients
provides a low but sustained glucose response and was provided at the start
of their normal dark cycle. VO2, VCO2 and respiratory exchange ratio (RER,
VCO2/VO2) were monitored.
Malonyl CoA assay
Malonyl CoA levels were measured in SD rat tissues from animals treated
with the same feeding paradigm as described above and sacrificed 1.5 hr af-
ter drug treatment. Tissues were harvested, immediately frozen in liquid ni-
trogen and then homogenized in a 1:10 volume (w/v) of ice-cold 5% sulfosa-
licylic acid containing 50 mM dithioerythritol. Homogenates were centrifuged
at 15,000 3 g for 60 min at 2ºC and the supernatants filtered through a 0.22
micron filter (Ultrafree-MC, Millipore Corporation, Bedford, Massachusetts).
Samples were stored at –80ºC prior to liquid chromatography mass spec-
trometry analysis. HPLC was run at binary mode (A: 5 mM dimethylbutyl-
amine and 6 mM HOAc; B: 0.1% formic acid in CH3CN [EMD Chemicals,
Gibbstown, New Jersey]) at 200 mL/min with the third pump to deliver post
column mixing solvent CH3CN. The data were acquired on an Applied Bio-
system Pulsar I quadrapole-TOF mass spectrometer (Foster City, California)
using positive ion TOFMSmode (Lan Gao, 2005 ASMS conference abstract).
Reagents were supplied by Sigma unless stated otherwise.
ob/ob studies
After acclimation ob/ob and lean mice were randomized to the various treat-
ment groups by body weight and fed glucose levels (tail snip) at 8 AM. Base-
line plasma insulin samples were also taken from a subset of the animals rep-
resenting each treatment group (n = 10 ob/ob and n = 10 lean ob/+
littermates; ELISA, ALPCO Diagnostics, Windham, NH). Two separate ob/
ob and lean littermate studies were completed: 1) an initial 5 day study,
and 2) a 14 day study to examine efficacy and more completely characterize
the body weight change observed in the 5 day study. Treatment groups for
the 5 day study were as follows: ob/ob vehicle (0.2% hydroxypropyl methyl-
cellulose [HPMC], i.p., b.i.d.), A-592107 (10 or 100 mg/kg, i.p., b.i.d.),413
A R T I C L EA-769662 (3 or 30 mg/kg, i.p., b.i.d.), AICAR (375 mg/kg, s.c., b.i.d.), or met-
formin (450 mg/kg, p.o., q.d., with vehicle in PM), and lean littermates treated
with vehicle (i.p., b.i.d.), (n = 10 per group). Treatment groups for the 14 day
ob/ob and lean littermate study were as follows: ob/ob vehicle (0.2% HPMC,
i.p., b.i.d.), A-769662 (3, 10, or 30 mg/kg, i.p., b.i.d.), or metformin (as de-
scribed above for the 5 day study) (n = 10 per group), and lean littermates
treated with vehicle or 30 mg/kg of A-769662 (i.p., b.i.d.).
For the 5 day study plasma glucose levels were determined at baseline as
described above, and 1 hr post dose on day 5 at 9 AM. After animals were
weighed and blood samples were taken, animals were sacrificed by CO2 as-
phyxiation followed by a cardiac venipuncture. In the 14 day study nonfasting
plasma glucose levels (tail snip) were determined at baseline on day 1 (as de-
scribed above), and days 5, 8, and 14 and 1 hr postdose for these days. After
measurements were taken, animals were sacrificed as described above. For
both experiments terminal blood samples were used for determination of
plasma insulin, FFA and triglyceride levels. Additionally, the following tissues
were harvested and frozen immediately in liquid nitrogen for further analysis:
liver, epididymal fat pad, skeletal muscle, and brain.
Two additional ob/ob experiments were performed under the same condi-
tions as described above. In the first, mice (n = 10 per group) were sacrificed
after an overnight fast and either 24 hr or 5 days of dosing. Following random-
ization mice were dosed bid, fasted overnight prior to sacrifice, and dosed 1
hr prior to sacrifice. In the second, both overnight fasted (n = 10 per group)
and postprandial (n = 5 per group) sacrifice conditions on day 5 at 9 AM (1
hr postfinal dose) were studied. Estimated food intake was determined in
this study for the first 3 days of the experiment by food weight difference
from days 0-to-1, 1-to-2 and 2-to-3. There were n = 15 mice per treatment
arm and they were housed 5 per cage, therefore data are from each of the
3 cages for each treatment divided by the number of mice/cage, mean6S.E.
Processing and analysis of samples from ob/ob experiments
Plasma glucose was determined in tail snip samples by the glucose oxidase
method (Precision PCx glucose meter, Abbott Laboratories, North Chicago,
Illinois). Day 5 1 hr post dose plasma insulin samples were taken from each
treatment group (ELISA, ALPCO Diagnostics, Windham, New Hampshire).
Plasma free fatty acids (FFAs) and triglycerides (TGs) were determined by
standard enzymatic assays (FFA, Wako, Richmond, Virginia and TG, Sigma,
St. Louis, Missouri, respectively). Liver fat area fraction in tissue sections was
determined by Oil Red O (Poly Scientific, Bay Shore, New York) staining. Im-
ages were acquired using a Leica DMIRE microscope (Leica Microsystems,
Wetzlar, Germany), an Optronics DEI-750 video camera (Optronics, Goleta,
California) and MetaMorph software (Universal Imaging, Downington, Penn-
sylvania). Ten random images were taken from each tissue section, using
a 203 microscope objective and a motorized scanning stage. Images were
analyzed using MetaMorph image analysis software. The images were
thresholded to detect the Oil Red O stained fat droplets. Plasma and tissue
levels of A-592107 and A-769662 were determined by HPLC.
ACC activity assay
ACC activity was assayed by measuring the incorporation of (14C)HCO3
- into
malonyl CoA. Tissueswere homogenized in a 103 volume (w/v) of buffer con-
taining 50 mM Tris (pH 7.4), 2 mM DTT, 2.5 mg/ml sucrose, 0.6 mg/ml digi-
tonin and Protease Inhibitor Cocktail and homogenates were centrifuged at
15,000 3 g for 100 min at 2ºC. After normalizing protein concentrations
ACC activity was measured in 96-well, white-walled plates (Wallac) using
an assay reaction mix of 50 mM Hepes (pH 7.5) 10 mM potassium citrate,
10 mM MgCl2, 4 mM potassium carbonate (pH 8.3), 0.5 mM ATP, 0.4 mM
NaH14CO3 (Perkin Elmer), 0.25 mM acetyl CoA and 0.075% fatty acid-free
BSA. Plates were incubated at RT for 40 min before stopping the reaction
with the addition of .5 volume of 1 N HCl and allowed to stand ON at RT to
release unincorporated 14C. Scintillant was added (OptiPhase SuperMix,
Perkin Elmer) and cpmmeasured using aWallac Micro-Beta counter. Unless
otherwise noted, all reagents were supplied by Sigma.
Quantitation of mRNA
Total RNAs were extracted from liver using the Qiazol method (Qiagen, Va-
lencia, California). and the mRNA quantitated using a Platinum qRT-PCR
kit (Invitrogen) and an Applied Biosystems thermocycler. Primers were as
follows for 28S RNA, 28ST (Hex-TCA-CGACGGTCTAAACCCAGCTCACG),
28SF (TGTCTGAACCTGCGGTTCCCT), 28SR (TTCACCAAGCGTTCGATTG414TT) (Integrated DNA Technologies, Coralville, Iowa). Primers used for PEPCK
were PEPCK(T) (FAM-TGGCCAGCGCATGCGG), PEPCKF (GAAGGACAGA
CTCGCCCTATGT, PEPCKR (CAGGGGCCTCCAGC-ACAGAT) (Integrated
DNA Technologies). Primers for G6Pase were G6Pase(T) (Fam-TGCTCCCA
TTCCGTTCGCC, G6PaseF (TGCAAGGGAGAACTGAGCAA), G6PaseR (GG
ACCAAGGAAGCCACAATG) (Qiagen). Primers used for FAS were FAS(T)
(Fam-CACCAGAGATGCTCCGATCCCCA), FASF (TCCCCAGTTCCTGCACT
CA), FASR (TCCCCAGTTCCGCACTCA) (Operon Technologies, Alameda,
California). All samples were run in duplex with and normalized to 28S RNA.
Liver triglycerides
Liver tissue was homogenized in thirty volumes of ethanol (Polytron homog-
enizer, Brinkmann, Westbury, New York). Samples were vortexed, allowed to
settle and the supernatant was centrifuged at 15,000g for 10 min at room
temperature. To assay, 10 ml of PBS was first added to flat bottom polysty-
rene plates (Nalge Nunc, Westchester, New York) followed by 2.5 ml of
cleared supernatant. 300 ml Infinity Triglyceride Reagent (Thermo Electron,
Melbourne, Australia) was added to wells and the plate was incubated at
37ºC for 5 min. After cooling to room temperature, samples were read at
520 nm with a SpectraMax Plus spectrophotometer (Molecular Devices,
Sunnyvale, California).
Cross-reactivity assays
Cross-reactivity assays were performed by CEREP (www.cerep.com).
Supplemental data
Supplemental data include one table and can be found with this article online
at http://www.cellmetabolism.org/cgi/content/full/3/6/403/DC1/.
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